At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
In Brief
A Phase 3 clinical trial evaluating Caspofungin Acetate, Fluconazole, and 2 other interventions for Fungal Infection and Hematopoietic and Lymphoid Cell Neoplasm. Completed, enrolled 292 participants across 49 sites in 2 countries.
Detailed Summary
This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.
Study Details
Timeline
Interventions
Given IV
Given IV or PO
Optional correlative studies
Given IV or PO